| 3.035 0.074 (2.51%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.75 | 1-year : | 4.08 |
| Resists | First : | 3.21 | Second : | 3.5 |
| Pivot price | 2.97 |
|||
| Supports | First : | 2.75 | Second : | 2.29 |
| MAs | MA(5) : | 2.88 |
MA(20) : | 3.06 |
| MA(100) : | 3.39 |
MA(250) : | 3.9 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 21.2  |
D(3) : | 19.9 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 19.06 | Low : | 1.83 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NCEL ] has closed above bottom band by 28.8%. Bollinger Bands are 17.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.04 - 3.06 | 3.06 - 3.08 |
| Low: | 2.82 - 2.84 | 2.84 - 2.86 |
| Close: | 2.83 - 2.86 | 2.86 - 2.89 |
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Wed, 23 Sep 2026
NewcelX Ltd. SEC Filing (Sep 23, 2026) - Stock Titan
Fri, 31 Jul 2026
NewcelX Announces $1.4 Million Private Placement at 20% Premium to Market to Advance NCEL-101 for Type 1 Diabetes - Quiver Quantitative
Fri, 24 Jul 2026
NewcelX Ltd. Revenue Breakdown – NASDAQ:NCEL - TradingView
Mon, 09 Mar 2026
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 68 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 37 (K) |
| Shares Short P.Month | 57 (K) |
| EPS | -2.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -1.33 |
| PEG Ratio | 0 |
| Price to Book value | 1.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|